Premium
Bispecific Antibodies in the Treatment of Hematologic Malignancies
Author(s) -
Duell Johannes,
Lammers Philip E.,
Djuretic Ivana,
Chunyk Allison G.,
Alekar Shilpa,
Jacobs Ira,
Gill Saar
Publication year - 2019
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1396
Subject(s) - bispecific antibody , monoclonal antibody , antibody , medicine , antibody therapy , hematologic neoplasms , immune system , immunotherapy , immunology , cancer research , cancer
Monoclonal antibody therapies are an important approach for the treatment of hematologic malignancies, but typically show low single‐agent activity. Bispecific antibodies, however, redirect immune cells to the tumor for subsequent lysis, and preclinical and accruing clinical data support single‐agent efficacy of these agents in hematologic malignancies, presaging an exciting era in the development of novel bispecific formats. This review discusses recent developments in this area, highlighting the challenges in delivering effective immunotherapies for patients.